How We Manage Patients with Plasmacytomas

被引:12
作者
Fotiou, Despina [1 ]
Dimopoulos, Meletios A. [1 ]
Kastritis, Efstathios [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
关键词
Plasma cells; Tumor; Solitary lesion; Bone disease; Extramedullary; EXTRAMEDULLARY MULTIPLE-MYELOMA; POSITRON-EMISSION TOMOGRAPHY; SOLITARY BONE PLASMACYTOMA; STEM-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; COMPUTED-TOMOGRAPHY; PROGNOSTIC-FACTORS; CLINICAL-FEATURES; F-18-FDG PET/CT; PRESENTING FEATURES;
D O I
10.1007/s11899-018-0452-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). Recent Findings Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci. The role of flow cytometry and clonal plasma cell detection is currently under study together with other prognostic factors for the identification of patients with SP at high risk of progression to overt MM. Solitary plasmacytomas are treated effectively with local radiotherapy whereas systemic therapy is required at relapse. Clonal plasma cells that accumulate at extramedullary sites have distinct biological characteristics. Patients with MM and soft tissue involvement have poor outcomes and should be treated as ultra-high risk. Summary A revised definition of SP that distinguishes between true solitary clonal PC accumulations and SP with minimal bone marrow involvement should be considered to guide an appropriate therapeutic and follow-up approach. Future studies should be conducted to determine optimum treatment approaches for patients with MM and paraskeletal or extramedullary disease.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 99 条
[1]   SOLITARY PLASMACYTOMA PRODUCING CRANIAL NEUROPATHY [J].
ALEXANDER, MP ;
GOODKIN, DE ;
POSER, CM .
ARCHIVES OF NEUROLOGY, 1975, 32 (11) :777-778
[2]  
Alexiou C, 1999, CANCER, V85, P2305, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.3.CO
[3]  
2-V
[4]   Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: Identification of prognostic factors [J].
Anagnostopoulos, A ;
Gika, D ;
Hamilos, G ;
Zervas, K ;
Zomas, A ;
Pouli, A ;
Zorzou, M ;
Kastritis, E ;
Anagnostopoulos, N ;
Tassidou, A ;
Anagnostou, D ;
Dimopoulos, MA .
LEUKEMIA & LYMPHOMA, 2004, 45 (11) :2275-2279
[5]   Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma [J].
Avigdor, A ;
Raanani, P ;
Levi, I ;
Hardan, I ;
Ben-Bassat, I .
LEUKEMIA & LYMPHOMA, 2001, 42 (04) :683-+
[6]  
Aviles A, 1996, HEMATOL ONCOL, V14, P111, DOI 10.1002/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.3.CO
[7]  
2-7
[8]   The Arkansas approach to therapy of patients with multiple myeloma [J].
Barlogie, Bart ;
Anaissie, Elias ;
van Rhee, Frits ;
Pineda-Roman, Mauricio ;
Zangari, Maurizio ;
Shaughnessy, John ;
Epstein, Joshua ;
Crowley, John .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) :761-781
[9]  
Barosi G, 2004, HAEMATOLOGICA, V89, P717
[10]   HISTOLOGIC CLASSIFICATION AND STAGING OF MULTIPLE-MYELOMA - A RETROSPECTIVE AND PROSPECTIVE-STUDY OF 674 CASES [J].
BARTL, R ;
FRISCH, B ;
FATEHMOGHADAM, A ;
KETTNER, G ;
JAEGER, K ;
SOMMERFELD, W .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (03) :342-355